US FDA steps into high-price Makena preterm birth drug controversy
This article was originally published in Scrip
Executive Summary
The US FDA on 30 March threw itself into an erupting storm over the high price of KV Pharmaceuticals' drug used to prevent preterm birth, Makena (hydroxyprogesterone caproate).